To evaluate the Safety and efficacy of Unani formulations in the treatment of Ziabetus Sukari Qism e Sani (Diabetes Mellitus type-2)

Phase 2

• Conditions: Health Condition 1: E119- Type 2 diabetes mellitus without complicationsHealth Condition 2: E119- Type 2 diabetes mellitus without complicationsHealth Condition 3: null- Ziabetus Sukari Qism e Sani (Diabetes Mellitus type-2)

• Registration Number: CTRI/2015/03/005630
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

1.Patients of either sex in the age group of 18-65 years.

2.Fasting plasma glucose levels between 126 and 150 mg/dl

or

3.2hr plasma glucose levels between 200 and 250 mg/dl

(2 hours after ingestion of 75 gm of glucose in 300 ml of water)

and/or

4.Presence of any of the following classical symptoms and signs of diabetes mellitus:

•Utashmufrit (Polydipsia)

•Kasrat al-Bawl (Polyuria)

•Kasrat al-Ishtiha (Polyphagia)

•Bawl Layli (Nocturia)

•Iâ??ya (Fatigue)

•Naqs al-Wazn (Loss of Weight)

•Burning sensation in palm and soles

•Sadr (Giddiness)

•Naqs al-Shahwa (Loss of Libido)

Exclusion Criteria

Any one of the following:

•Subjects with fasting plasma glucose level >150 mg/dl and /or PP plasma glucose level > 250 mg/dl

•Diabetes Mellitus-Type I

•Patients on systemic corticosteroids/ disease modifying agents

•Ischemic Heart Disease/ Hypertension/ Hyperlipidemia

•Liver disorders SGPT >105 IU/L

•Impaired Renal function

•Anemia: Hb <8 gm/dl in Males and Hb <6 gm/dl in females

•Obese Subjects â?? BMI >30

•Pregnant and lactating women

•Any disorder requiring long-term treatment

•Patient on any other treatment including use of alternative medicine

Study & Design

• Study Type: Interventional
• Study Design: Not specified